Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Papamichail

Showing results (61-70 of 66) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 66 results.
Clinical Immunology (Orlando, Fla.)|July 21, 2018
Effects of HLA status and HER2 status on outcomes in breast cancer patients at risk for recurrence - Implications for vaccine trial designDoreen O Jackson, Francois A Trappey, G Travis Clifton, et al.
International Immunology|November 18, 2005
Effect of IL-21 on NK cells derived from different umbilical cord blood populationsSonia A Perez, Louisa G Mahaira, Panagiota A Sotiropoulou, et al.
Cytometry. Part B, Clinical Cytometry|June 24, 2005
Multicentre evaluation of stable reference whole blood for enumeration of lymphocyte subsets by flow cytometryCherry Edwards, Danielle Belgrave, George Janossy, et al.
Expert Opinion on Biological Therapy|September 8, 2011
AE37: a novel T-cell-eliciting vaccine for breast cancerAlan K Sears, Sonia A Perez, Guy T Clifton, et al.
Breast Cancer Research and Treatment|April 24, 2020
Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrenceTommy A Brown, Elizabeth A Mittendorf, Diane F Hale, et al.
Journal of Translational Medicine|December 16, 2011
Defining the critical hurdles in cancer immunotherapyBernard A Fox, Dolores J Schendel, Lisa H Butterfield, et al.
Pageof 7

Showing results (61-70 of 66) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 66 results.
Clinical Immunology (Orlando, Fla.)|July 21, 2018
Effects of HLA status and HER2 status on outcomes in breast cancer patients at risk for recurrence - Implications for vaccine trial designDoreen O Jackson, Francois A Trappey, G Travis Clifton, et al.
International Immunology|November 18, 2005
Effect of IL-21 on NK cells derived from different umbilical cord blood populationsSonia A Perez, Louisa G Mahaira, Panagiota A Sotiropoulou, et al.
Cytometry. Part B, Clinical Cytometry|June 24, 2005
Multicentre evaluation of stable reference whole blood for enumeration of lymphocyte subsets by flow cytometryCherry Edwards, Danielle Belgrave, George Janossy, et al.
Expert Opinion on Biological Therapy|September 8, 2011
AE37: a novel T-cell-eliciting vaccine for breast cancerAlan K Sears, Sonia A Perez, Guy T Clifton, et al.
Breast Cancer Research and Treatment|April 24, 2020
Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrenceTommy A Brown, Elizabeth A Mittendorf, Diane F Hale, et al.
Journal of Translational Medicine|December 16, 2011
Defining the critical hurdles in cancer immunotherapyBernard A Fox, Dolores J Schendel, Lisa H Butterfield, et al.
Pageof 7